#USA #San Diego #Class Action #Geron Corporation #Rytelo

Opportunity for Geron Corporation Investors

In recent developments concerning the Geron Corporation (NASDAQ: GERN), Robbins Geller Rudman & Dowd LLP has issued a call to investors who incurred substantial financial losses during the specified class period. Those who purchased or acquired Geron securities from February 28, 2024, to February 25, 2025, have until May 12, 2025, to put themselves forward as lead plaintiffs in a significant class action lawsuit pending in the Northern District of California.

Background on the Lawsuit

The class action, identified as Dabestani v. Geron Corporation, accuses Geron and various executive members of breaching the Securities Exchange Act of 1934. A subsequent complaint, Potvin v. Geron Corporation, has also been filed with similar claims. This legal action is primarily fueled by allegations that the company misled investors regarding its financial health and the anticipated performance of its flagship product, Rytelo (imetelstat).

According to the lawsuit, Geron executives allegedly created a false narrative about the company's revenue prospects and the success of Rytelo in the marketplace. During the class period, investors were reportedly misinformed about critical factors affecting sales, including competition, market penetration challenges, and the necessary monitoring demanded by the treatment.

Details of the Accusations

Specifically, the complaint outlines that defendants repeatedly assured investors of a strong and growing market for Rytelo while downplaying the risks presented by seasonal fluctuations, competitive pressures from existing cancer therapies, and a lack of market awareness. The flawed messaging culminated in a startling discount of over 32% in Geron’s stock value following an announcement on February 26, 2025, regarding a significant downturn in Rytelo's market performance. This sharp decline was attributed to oversights in the growth forecasts and market dynamics, exposing vulnerabilities that the executives failed to disclose.

The Role of Lead Plaintiffs

The Private Securities Litigation Reform Act of 1995 offers any investor who experienced losses during the class period an opportunity to take on the role of lead plaintiff in the lawsuit. The lead plaintiff is generally viewed as someone with the most substantial interest in the outcome of the case, typically representing the collective interests of the class members. This position enables investors to direct how the lawsuit unfolds while having the option to choose their legal representation.

It is crucial for interested investors to act swiftly, as the deadline to establish leadership in the case approaches. Investors wishing to join the legal battle can provide their contact information through Robbins Geller’s designated platform for this case.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a prominent law firm that has garnered a reputation for representing investors in securities fraud and shareholder litigation. Over the past five years, it has achieved recognition as the top firm in securing monetary recoveries for investors, recovering over $2.5 billion in class action cases in 2024 alone. The firm operates with a team of 200 lawyers across 10 offices, specializing in securing justice for shareholders who have been wronged. For further details about the ongoing litigation and firm activities, investors are encouraged to visit the firm's website.

Conclusion

For Geron Corporation investors affected by recent events, the upcoming class action lawsuit presents a significant opportunity to seek financial recovery and hold the company accountable for its alleged misrepresentations. Those faced with pronounced losses during the class period are urged to consider initiating their participation as lead plaintiffs to ensure their voices are heard in this critical legal matter.